Literature DB >> 31857362

Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk.

Jill Corre1, Lydia Montes2, Elodie Martin3, Aurore Perrot4, Denis Caillot5, Xavier Leleu6, Karim Belhadj7, Thierry Facon8, Cyrille Hulin9, Mohamad Mohty10, Jean Fontan11, Margaret Macro12, Sabine Brechignac13, Arnaud Jaccard14, Anne-Marie Stoppa15, Frederique Orsini-Piocelle16, Didier Adiko17, Laurent Voillat18, Faiza Keddar19, Marly Barry20, Helene Demarquette21, Marie-Noelle Certain22, Isabelle Plantier23, Murielle Roussel24, Benjamin Hébraud24, Thomas Filleron3, Michel Attal24, Hervé Avet-Loiseau25.   

Abstract

Keywords:  Cytogenetics and Molecular Genetics; Multiple Myeloma; early relaspe

Year:  2019        PMID: 31857362      PMCID: PMC7556617          DOI: 10.3324/haematol.2019.236588

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy.

Authors:  Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Philip R Greipp; Mark R Litzow; Kimberly J Henderson; Scott A Van Wier; Greg J Ahmann; Rafael Fonseca
Journal:  Blood       Date:  2005-06-23       Impact factor: 22.113

2.  Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.

Authors:  Sathish Gopalakrishnan; Anita D'Souza; Emma Scott; Raphael Fraser; Omar Davila; Nina Shah; Robert Peter Gale; Rammurti Kamble; Miguel Angel Diaz; Hillard M Lazarus; Bipin N Savani; Gerhard C Hildebrandt; Melhem Solh; Cesar O Freytes; Cindy Lee; Robert A Kyle; Saad Z Usmani; Siddhartha Ganguly; Amer Assal; Jesus Berdeja; Abraham S Kanate; Binod Dhakal; Kenneth Meehan; Tamila Kindwall-Keller; Ayman Saad; Frederick Locke; Sachiko Seo; Taiga Nishihori; Usama Gergis; Cristina Gasparetto; Tomer Mark; Yago Nieto; Shaji Kumar; Parameswaran Hari
Journal:  Biol Blood Marrow Transplant       Date:  2018-12-21       Impact factor: 5.742

3.  High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma.

Authors:  Bruno Paiva; Norma C Gutiérrez; Laura Rosiñol; María-Belén Vídriales; María-Ángeles Montalbán; Joaquín Martínez-López; María-Victoria Mateos; María-Teresa Cibeira; Lourdes Cordón; Albert Oriol; María-José Terol; María-Asunción Echeveste; Raquel de Paz; Felipe de Arriba; Luis Palomera; Javier de la Rubia; Joaquín Díaz-Mediavilla; Anna Sureda; Ana Gorosquieta; Adrian Alegre; Alejandro Martin; Miguel T Hernández; Juan-José Lahuerta; Joan Bladé; Jesús F San Miguel
Journal:  Blood       Date:  2011-11-29       Impact factor: 22.113

4.  Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

Authors:  S Vincent Rajkumar; Jean-Luc Harousseau; Brian Durie; Kenneth C Anderson; Meletios Dimopoulos; Robert Kyle; Joan Blade; Paul Richardson; Robert Orlowski; David Siegel; Sundar Jagannath; Thierry Facon; Hervé Avet-Loiseau; Sagar Lonial; Antonio Palumbo; Jeffrey Zonder; Heinz Ludwig; David Vesole; Orhan Sezer; Nikhil C Munshi; Jesus San Miguel
Journal:  Blood       Date:  2011-02-03       Impact factor: 22.113

5.  Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance.

Authors:  Wilfrid Jaksic; Suzanne Trudel; Hong Chang; Young Trieu; Xi Qi; Joseph Mikhael; Donna Reece; Christine Chen; A Keith Stewart
Journal:  J Clin Oncol       Date:  2005-08-29       Impact factor: 44.544

6.  Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma.

Authors:  Aurore Perrot; Valérie Lauwers-Cances; Elodie Tournay; Cyrille Hulin; Marie-Lorraine Chretien; Bruno Royer; Mamoun Dib; Olivier Decaux; Arnaud Jaccard; Karim Belhadj; Sabine Brechignac; Jean Fontan; Laurent Voillat; Hélène Demarquette; Philippe Collet; Philippe Rodon; Claudine Sohn; François Lifermann; Frédérique Orsini-Piocelle; Valentine Richez; Mohamad Mohty; Margaret Macro; Stéphane Minvielle; Philippe Moreau; Xavier Leleu; Thierry Facon; Michel Attal; Hervé Avet-Loiseau; Jill Corre
Journal:  J Clin Oncol       Date:  2019-05-15       Impact factor: 44.544

7.  Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials.

Authors:  Brian G M Durie; Joth Jacobson; Bart Barlogie; John Crowley
Journal:  J Clin Oncol       Date:  2004-04-26       Impact factor: 44.544

8.  Impact of early relapse after auto-SCT for multiple myeloma.

Authors:  S Kumar; S T Mahmood; M Q Lacy; A Dispenzieri; S R Hayman; F K Buadi; D Dingli; S V Rajkumar; M R Litzow; M A Gertz
Journal:  Bone Marrow Transplant       Date:  2008-06-30       Impact factor: 5.483

Review 9.  How I treat first relapse of myeloma.

Authors:  Jean Luc Harousseau; Michel Attal
Journal:  Blood       Date:  2017-07-05       Impact factor: 22.113

10.  Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents.

Authors:  N Majithia; S V Rajkumar; M Q Lacy; F K Buadi; A Dispenzieri; M A Gertz; S R Hayman; D Dingli; P Kapoor; L Hwa; J A Lust; S J Russell; R S Go; R A Kyle; S K Kumar
Journal:  Leukemia       Date:  2016-05-23       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.